Adalimumab — Drug Intelligence | 46 EU Trials

Filter these 46 trials by condition, phase, country and more.

Open in Search →

46 Registered trials

19 Recruiting

17 Completed trials

34 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 13 Phase II: 8 Phase I/II: 1 Phase III/IV: 4 Phase IV: 19 Phase I (FiH): 1

Oversight events:

1 temporary halt 1 corrective measure across 2 trials

View oversight register →

Indications tested

Rheumatoid arthritis 4 Juvenile idiopathic arthritis 3 Colitis ulcerative 2 Crohn's disease 2 Juvenile psoriatic arthritis 1 Uveitis 1 Infective uveitis 1 Psoriatic arthropathy 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 5 Assistance Publique Hopitaux De Paris 5 Centre Hospitalier Universitaire De Saint Etienne 3 Eli Lilly & Co. 3 Universitair Medisch Centrum Groningen 3 Centre Hospitalier Universitaire Amiens Picardie 2 UZ Leuven 2 Aalborg University Hospital 1 Alimentiv Inc. 1 Almirall S.A. 1 Bristol-Myers Squibb Services Unlimited Company 1 Centre Hospitalier Universitaire De Bordeaux 1

All trials

46 total

Evaluation of a therapeutic de-eScalation strategy based on therapeutic drug MOnitOring in chronic non-infectious uveitis Treated witH adali… Pending

2023-509733-39-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr… Pending

2024-514633-38-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch Pending

2024-514848-88-00 Phase II 1 country Assistance Publique Hopitaux De Paris
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WIT… Pending

2024-517314-15-00 Phase III/IV 1 country Centre Hospitalier Universitaire Amiens Picardie
Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial Pending

2024-519891-17-00 Phase II 1 country Universitetssykehuset Nord-Norge HF
Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with … Pending

2025-520632-42-00 Phase III 1 country Centre Hospitalier Universitaire Rouen
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending

2025-520923-25-00 Phase III 3 countries Duke Clinical Research Institute
The OASE study Pending

2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
Discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors Pending

2026-525316-33-00 Phase IV 1 country Sint Maartenskliniek Stichting
The Treat-JIA trial Pending

2026-525611-13-00 Phase IV 1 country Oslo Universitetssykehus HF
Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Phase II 6 countries Almirall S.A.
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting

2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant… Recruiting

2023-505678-14-00 Phase II 18 countries AbbVie Deutschland GmbH & Co. KG
Efficacy, safety, tolerability, and pharmacokinetics of risankizumab in pediatric subjects with active juvenile psoriatic arthritis Recruiting

2023-506026-36-00 Phase III 5 countries AbbVie Deutschland GmbH & Co. KG
STARS (Secukinumab in TAkayasu ARteritiS) Recruiting

2024-516215-24-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory… Recruiting

2025-521420-30-00 Phase I/II 1 country Universitair Medisch Centrum Groningen
Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting

2024-511442-39-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
Design and evaluation of an individualized biodrug tapering strategy based on biodrug dosage: the MONITORA study_STEP1 Recruiting

2024-514313-35-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
MOVE-JIA trial Recruiting

2024-513017-12-00 Phase IV 1 country Oslo University Hospital HF
FREE-study Recruiting

2024-516277-68-00 Phase IV 3 countries Universitair Medisch Centrum Groningen
A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting

2023-509096-16-00 Phase IV 8 countries Alimentiv Inc.
“Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent n… Recruiting

2023-505112-38-00 Phase III/IV 1 country Assistance Publique Hopitaux De Paris
Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi… Recruiting

2023-508154-25-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting

2024-513371-41-00 Phase II 1 country Assistance Publique Hopitaux De Paris

Showing 1–24 of 46 trials

← All drugs A–Z